Ab­b­Vie opens up to big­ger deals as com­pe­ti­tion heats up — re­port; Small ra­dio­phar­ma­ceu­ti­cal play­er goes pub­lic via re­verse merg­er

Ab­b­Vie is look­ing to make a push this year on new drugs — and it’s ready to spend for it.

Ac­cord­ing to a re­port from the Wall Street Jour­nal, Ab­b­Vie is keen to re­place the po­ten­tial sales that could be lost from Hu­mi­ra and will be re­mov­ing its in-house $2 bil­lion lim­it of the size of its deals to add on more prod­ucts. Ab­b­Vie CEO Richard Gon­za­lez told the Jour­nal that the Illi­nois-based phar­ma has room to do more deals. The Jour­nal al­so stat­ed that Ab­b­Vie will look to se­cure four ap­provals by the end of 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER